In re BioMarin Pharmaceutical Inc. Securities Litigation

CourtDistrict Court, N.D. California
DecidedFebruary 28, 2022
Docket3:20-cv-06719
StatusUnknown

This text of In re BioMarin Pharmaceutical Inc. Securities Litigation (In re BioMarin Pharmaceutical Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re BioMarin Pharmaceutical Inc. Securities Litigation, (N.D. Cal. 2022).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 IN RE BIOMARIN PHARMACEUTICAL 7 INC. SECURITIES LITIGATION Case No. 3:20-cv-06719-WHO

8 ORDER DENYING MOTION FOR 9 LEAVE TO FILE A MOTION TO RECONSIDER OR CERTIFY ISSUE 10 FOR INTERLOCUTORY APPEAL 11 Re: Dkt. No. 85

12 13 I previously denied a motion to dismiss this putative securities class action. I found, 14 among other things, that the statements at issue were not protected by the safe harbor of the 15 Private Securities Litigation Reform Act (“PSLRA”). The defendants (collectively, “BioMarin”) 16 move for leave to file a motion to reconsider one aspect of that decision, or to certify the issue for 17 interlocutory appeal in the alternative. BioMarin argues that I employed an overly demanding 18 standard for whether “meaningful cautionary language” was adequate to relieve them of liability 19 under the safe harbor. It contends that the standard relied on legal principles that predated the 20 PSLRA and were overturned by it. The motion is denied. As I explain, the standard I employed 21 faithfully applies Ninth Circuit and Supreme Court precedent. 22 BACKGROUND 23 The allegations in and history of this case are surveyed in detail in the order for which 24 BioMarin seeks reconsideration. See Order on Motion to Dismiss (“Prior Order”) [Dkt. No. 77]. 25 In brief, the plaintiffs alleged that BioMarin and several of its executives “misled investors about 26 the progress of a new hemophilia therapy it was developing. According to them, the defendants 27 intentionally misrepresented their interactions with the Food and Drug Administration [] about the 1 motion to dismiss. One of BioMarin’s arguments was that the 13 statements at issue (the 2 “Challenged Statements”) were shielded by the PSLRA’s safe harbor. See id. 9. I disagreed, 3 explaining that the statements were neither accompanied by “meaningful cautionary language” nor 4 shown to be made without actual knowledge of their falsity. See id. 9–12. 5 LEGAL STANDARD 6 I. MOTION FOR LEAVE TO FILE A MOTION TO RECONSIDER 7 Civil Local Rule 7-9 governs motions for reconsideration of interlocutory orders prior to 8 “the entry of a judgment adjudicating all of the claims and the rights and liabilities of all the 9 parties in a case.” CIV. L. R. 7-9(a). Under that rule, “any party may make a motion before a 10 Judge requesting that the Judge grant the party leave to file a motion for reconsideration of any 11 interlocutory order on any ground set forth in Civil L.R. 7-9(b). No party may notice a motion for 12 reconsideration without first obtaining leave of Court to file the motion.” Id. Under Rule 7-9(b),

13 The moving party must specifically show reasonable diligence in bringing the motion and one of the following: (1) That at the time of the motion for leave, a material difference in 14 fact or law exists from that which was presented to the Court before entry of the interlocutory order for which reconsideration is sought. The party also must show that in 15 the exercise of reasonable diligence the party applying for reconsideration did not know 16 such fact or law at the time of the interlocutory order; or (2) The emergence of new material facts or a change of law occurring after the time of such order; or (3) A manifest 17 failure by the Court to consider material facts or dispositive legal arguments which were presented to the Court before such interlocutory order. 18 Id. 7-9(b). 19 Even if a motion does not satisfy Rule 7-9, district courts have the inherent authority to 20 modify interlocutory orders prior to entry of final judgment. Amarel v. Connell, 102 F.3d 1494 21 (9th Cir. 1996), as amended (Jan. 15, 1997). But generally, “[r]econsideration is appropriate if the 22 district court (1) is presented with newly discovered evidence, (2) committed clear error or the 23 initial decision was manifestly unjust, or (3) if there is an intervening change in controlling law” 24 and any other circumstances warranting reconsideration would be “highly unusual.” Sch. Dist. 25 No. 1J, Multnomah Cty., Or. v. ACandS, Inc., 5 F.3d 1255, 1263 (9th Cir. 1993). 26 II. MOTION FOR CERTIFICATION FOR INTERLOCUTORY APPEAL 27 Under 28 U.S.C. § 1292(b), “[w]hen a district judge, in making in a civil action an order 1 not otherwise appealable under this section, shall be of the opinion that such order involves a 2 controlling question of law as to which there is substantial ground for difference of opinion and 3 that an immediate appeal from the order may materially advance the ultimate termination of the 4 litigation, he shall so state in writing in such order.” Then, the court of appeals may either permit 5 the appeal or not. See 28 U.S.C. § 1292(b). Each of these requirements—(1) a controlling 6 question of law, (2) substantial grounds for difference of opinion, and (3) materially advancing the 7 termination of the litigation—must be met to certify a question for interlocutory appeal. See 8 ICTSI Oregon, Inc. v. Int'l Longshore & Warehouse Union, 22 F.4th 1125, 1130 (9th Cir. 2022). 9 DISCUSSION 10 I. MOTION FOR LEAVE TO FILE A MOTION TO RECONSIDER 11 BioMarin argues that the Prior Order employed an incorrect standard for assessing the 12 “cautionary language” prong of the PSLRA’s safe-harbor. See Motion for Leave to Seek 13 Reconsideration or to Certify Question for Interlocutory Appeal (“Mot.”) [Dkt. No. 85]. 14 According to it, the Prior Order utilized legal principles from before the enactment of the PSLRA 15 that the PSLRA has since displaced. See id. 4–9. Under that new standard, BioMarin contends, 16 five of the 13 statements would have been shielded by the safe harbor. Id. 10 n.3 (listing 17 statements). For the reasons that follow, I disagree. 18 The PSLRA creates a “safe harbor” for certain forward-looking statements:

19 a person . . . shall not be liable with respect to any forward-looking statement, whether written or oral, if and to the extent that— 20 (A) the forward-looking statement is— 21

(i) identified as a forward-looking statement, and is accompanied by 22 meaningful cautionary statements identifying important factors that 23 could cause actual results to differ materially from those in the forward- looking statement; or 24 (ii) immaterial; or 25 (B) the plaintiff fails to prove that the forward-looking statement— 26 (i) if made by a natural person, was made with actual knowledge by that 27 person that the statement was false or misleading; or (I) made by or with the approval of an executive officer of that 1 entity; and

2 (II) made or approved by such officer with actual knowledge by that officer that the statement was false or misleading. 3 15 U.S.C. § 78u-5(c)(1). 4 This motion concerns the “meaningful cautionary language” prong. In the Prior Order, I 5 described the legal test for that prong this way: 6

To determine whether “cautionary language” is adequate, courts ask whether the 7 cautionary statements “precise[ly]” and “directly address” the alleged misrepresentations. 8 Provenz v. Miller, 102 F.3d 1478, 1493 (9th Cir. 1996) (internal quotation marks and citation omitted). “Blanket warnings that securities involve a high degree of risk [are] 9 insufficient to ward against a federal securities fraud claim.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Virginia Bankshares, Inc. v. Sandberg
501 U.S. 1083 (Supreme Court, 1991)
Cutera Securities Litigation v. Conners
610 F.3d 1103 (Ninth Circuit, 2010)
School District No. 1j, Multnomah County, Oregon v. Acands, Inc., a Pennsylvania Corporation E.J. Bartells Company, a Washington Corporation A.P. Green Refractories Company, School District No. 1j, Multnomah County, Oregon v. Acands, Inc., a Pennsylvania Corporation, and Fibreboard Corp., a Delaware Corporation as Successor in Interest to the Paraffine Companies, Inc., Pabco Products, Inc., Fibreboard Paper Products Corporation, Plant Rubber & Asbestos Works and Plant Rubber & Asbestos Co., School District No. 1j, Multnomah County, Oregon v. Acands, Inc., a Pennsylvania Corporation Armstrong Cork Company, Inc., a Delaware Corporation Atlas Asbestos Company, Inc., a Canadian Corporation, and Keene Corporation, a New York Corporation Individually and as Successor in Interest to the Baldwin Ehret Hill Company, School District No. 1j, Multnomah County, Oregon v. Acands, Inc., a Pennsylvania Corporation Armstrong Cork Company, Inc., a Delaware Corporation Atlas Asbestos Company, Inc., a Canadian Corporation, and Us Gypsum Company, a Delaware Corporation, School District No. 1j, Multnomah County, Oregon v. Acands, Inc., a Pennsylvania Corporation Armstrong Cork Company, Inc., a Delaware Corporation Atlas Asbestos Company, Inc., a Canadian Corporation, and Owens-Corning Fiberglass Corporation, School District No. 1j, Multnomah County, Oregon v. Acands, Inc., a Pennsylvania Corporation Armstrong Cork Company, Inc., a Delaware Corporation Atlas Asbestos Company, Inc., a Canadian Corporation, and Flintkote Company, a Delaware Corporation, School District No. 1j, Multnomah County, Oregon v. Acands, Inc., a Pennsylvania Corporation Atlas Asbestos Company, Inc., a Canadian Corporation, and Armstrong Cork Company, Inc., a Delaware Corporation
5 F.3d 1255 (Ninth Circuit, 1993)
In Re Donald J. Trump Casino Securities Litigation--Taj Mahal Litigation. Sidney L. Kaufman, Suing Individually and on Behalf of a Class of Persons Similarly Situated Jerome Schwartz, Suing Individually and on Behalf of a Class of Persons Similarly Situated Peter Stuyvesant, Ltd., on Behalf of Itself and All Others Similarly Situated Susan Cagan Eric Cagan David E. Dougherty Jean Curzio Alexander L. Charnis Dorothy Arkell Fred Glossner Herman Krangel Robert Kloss Helen Kloss Fairmount Financial Corp. Joanne Gollomp Dino Del Zotto v. Trump's Castle Funding Trump's Castle Associates Limited Partnership, a New Jersey Limited Partnership Trump Taj Mahal Funding, Inc., a New Jersey Corporation Trump Taj Mahal Associates Limited Partnership, a New Jersey Limited Partnership Donald J. Trump Robert S. Trump John O'DOnnell Nathan Katz Tim Maland Francisco Tejeda Julian Menarguez Harvey I. Freeman Paul Henderson Patrick C. McKoy Edward M. Tracy Michael S. Vautrin Jeffrey A. Ross John P. Belisle Timothy G. Rose Lori Taylor C. "Bucky" Willard the Trump Organization, Inc. Trump Taj Mahal, Inc. Merrill Lynch, Pierce, Fenner & Smith Incorporated. Sidney L. Kaufman, Suing Individually and on Behalf of a Class of Persons Similarly Situated v. Trump's Castle Funding Trump's Castle Associates Limited Partnership, a New Jersey Limited Partnership Trump Taj Mahal Funding, Inc., a New Jersey Corporation Trump Taj Mahal Associates Limited Partnership, a New Jersey Limited Partnership Donald J. Trump. Jerome Schwartz, Suing Individually and on Behalf of a Class of Persons Similarly Situated v. Trump's Castle Funding, Inc. (A New Jersey Corporation) Trump's Castle Associates Limited Partnership (A New Jersey Limited Partnership) Trump Taj Mahal Funding, Inc. (A New Jersey Corporation) Trump Taj Mahal Associates Limited Partnership (A New Jersey Limited Partnership) Donald J. Trump. Peter Stuyvesant, Ltd., on Behalf of Itself and All Others Similarly Situated v. Donald J. Trump Robert S. Trump John O'DOnnell Trump Plaza Funding, Inc. Nathan Katz Tim Maland Trump Plaza Associates Francisco Tejeda Julian Menarguez Harvey I. Freeman Paul Henderson Patrick C. McKoy Edward M. Tracy Michael S. Vautrin Jeffrey A. Ross John P. Belisle Timothy G. Rose Trump's Castle Funding, Inc. Lori Taylor Trump's Castle Associates Limited Partnership. Susan Cagan Eric Cagan David E. Dougherty Jean Curzio v. Donald J. Trump Robert S. Trump Harvey I. Freeman C. "Bucky" Willard Trump Taj Mahal Funding, Inc. Trump Taj Mahal Associates Limited Partnership the Trump Organization, Inc. Trump Taj Mahal Incorporated Merrill Lynch, Pierce, Fenner & Smith Incorporated. Alexander L. Charnis Dorothy Arkell v. Donald J. Trump Robert S. Trump Harvey I. Freeman C. "Bucky" Willard Trump Taj Mahal Funding, Inc. Trump Taj Mahal Associates Limited Partnership the Trump Organization, Inc. Merrill Lynch, Pierce, Fenner & Smith Incorporated. Fairmont Financial Corp. Joanne Gollomp, on Behalf of Themselves and All Others Similarly Situated v. Donald J. Trump Harvey S. Freeman Robert S. Trump the Trump Organization, Inc. Merrill Lynch, Pierce, Fenner & Smith Incorporated Trump Taj Mahal Funding, Inc. Trump Taj Mahal, Inc. Trump Taj Mahal Associates Limited Partnership. Robert Kloss Helen Kloss v. Donald J. Trump Robert S. Trump Harvey I. Freeman C. "Bucky" Willard Trump Taj Mahal Associates Limited Partnership the Trump Organization, Inc. Trump Taj Mahal, Inc. Merrill Lynch, Pierce, Fenner & Smith Incorporated. Fred Glossner Herman Krangel v. Donald J. Trump Harvey S. Freeman Robert S. Trump the Trump Organization, Inc. Merrill Lynch, Pierce, Fenner & Smith Incorporated Trump Taj Mahal Funding, Inc. Trump Taj Mahal, Inc. Trump Taj Mahal Associates Limited Partnership. Dino Del Zotto v. Donald J. Trump Robert S. Trump Harvey I. Freeman C. "Bucky" Willard Trump Taj Mahal Funding, Inc. Trump Taj Mahal Associates the Trump Organization, Inc. Trump Taj Mahal, Inc. Merrill Lynch, Pierce, Fenner & Smith Incorporated, Joanne Gollomp, Susan Cagan, Eric Cagan, David E. Dougherty, Jean Curzio, Robert and Helen Kloss, Fred Glossner, Herman Krangel, Sidney Kaufman, Jerome Schwartz, Dino Del Zotto, Alexander L. Charnis and Dorothy Arkell, on Behalf of Themselves and All Others Similarly Situated
7 F.3d 357 (Third Circuit, 1993)
In Re Worlds Of Wonder Securities Litigation
35 F.3d 1407 (Ninth Circuit, 1994)
In Re Immune Response Securities Litigation
375 F. Supp. 2d 983 (S.D. California, 2005)
Ictsi Oregon, Inc. v. Ilwu
22 F.4th 1125 (Ninth Circuit, 2022)
Provenz v. Miller
102 F.3d 1478 (Ninth Circuit, 1996)
Amarel v. Connell
102 F.3d 1494 (Ninth Circuit, 1996)
In re Egalet Corp.
340 F. Supp. 3d 479 (E.D. Pennsylvania, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
In re BioMarin Pharmaceutical Inc. Securities Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-biomarin-pharmaceutical-inc-securities-litigation-cand-2022.